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Abstract
Background: Pregabalin, a gabapentinoid, is an adjuvant analgesic for treatment of neuropathic pain, but it has
serious adverse effects such as somnolence and dizziness, particularly in elderly patients. Although decreased renal
function is considered to the contributing factor for high frequency of these adverse effects in elder patients, only a
few systematic clinical investigations, especially for hospitalized patients, have been performed on factors that might
affect the incidence of its adverse effects. In this study, we performed a retrospective study on the effect of
concomitant drugs on induction of somnolence and dizziness as adverse effects of pregabalin in hospitalized patients.
Methods: The subjects were all pregabalin-administered patients in Shiga University of Medical Science Hospital from
September 2010 to September 2012, and the subject number was 195. Multivariate logistic regression analysis was
performed to determine predictors of the adverse effects, creatinine clearance, duration of pregabalin therapy, initial
and maintenance doses of pregabalin, and concomitant drugs, including hypoglycemic drugs, anti-hypertensive ones,
non-steroidal anti-inflammatory ones, opioids and central nervous system depressants, being used as independent
variables.
Results: The median initial doses of pregabalin in each renal function group were the same with the case of the
defined dose. Although renal function is a well-known factor for prediction of development of adverse effects of
pregabalin, we did not detect significant contribution of it. Alternatively, it was demonstrated that concomitant
administration of opioids was the significant factor of the incidence of somnolence and dizziness. The first onset date
of the adverse effects was frequently detected in the early days of the pregabalin therapy.
Conclusions: The fine tuning of pregabalin dosage schedule based on the renal function appeared to be critical for
prevention of development of its adverse effects. Adverse effects tended to develop in the initial phase of pregabalin
therapy. Concomitant administration of opioids with pregabalin has the potential to increase the incidence of adverse
effects, and thus much more careful attention has to be paid especially in those situations.
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Background
Pain is divided into two phenotypes, nociceptive and neuro-
pathic pain. The former is usually treated with conventional
analgesics such as non-steroidal anti-inflammatory drug
(NSAID) and opioids according to the WHO’s pain ladder.
As for the latter, on the other hand, in addition to conven-
tional analgesics, anti-depressants and anti-convulsants
are used as adjuvant ones [1]. However, in the clinical situ-
ation, since patients often suffer from both pain pheno-
types, they receive combination therapy with conventional
and adjuvant analgesics [2–4]. Anti-convulsants, gabapen-
tin and pregabalin are recommended for the first-line
therapy in the guidelines for neuropathic pain, and are
widely used as adjuvant analgesics for the patients
with neuropathic pain, painful diabetic neuropathy, and
chemotherapy-induced peripheral neuropathy [5–7]. While
the efficacy for pain relief is similar for the two medica-
tions, pregabalin has pharmacokinetic/pharmacodynamic
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advantages compared to gabapentin such as higher affinity
for the α2δ subunit of voltage-dependent calcium chan-
nels [8, 9], more rapid onset of action, high oral bioavail-
ability and linear pharmacokinetics [10]. After intestinal
absorption, pregabalin in the plasma is mainly excreted
into the urine as an unchanged drug as in the case of
gabapentin, and thus its dose is determined based on renal
function indicated by creatinine clearance (CLCr) in pa-
tients [10]. Nevertheless, it is well-known that pregabalin
causes a lot of adverse effects in the clinical situation. In
the interim report of the Japanese post-marketing treat-
ment outcome study on pregabalin (Lyrica®), of which
most of the patients were outpatients, somnolence and
dizziness were found to be high frequency adverse effects
in elder patients [11]. In addition, such adverse effects are
reported to cause tumbling and traffic accidents [12].
Thus, the Pharmaceuticals and Medical Devices Agency
of Japan released a notice regarding use of pregabalin in
elder patients in July 2012. On the other hand, it is well-
known that drug-drug interaction is one of critical factors
for induction of adverse effects of either or both drugs,
but there are only a few systematic clinical studies on the
factors which affect development of adverse effects of
pregabalin [13, 14].
In this study, therefore, we performed a retrospective
study to determine whether drug-drug interaction of
pregabalin with concomitantly administered drugs was
one of the factors for induction of the adverse effects of
pregabalin in hospitalized patients.
Methods
Participants
This study was approved by the ethics committee of
Shiga University of Medical Science Hospital (#24-125).
The subjects were all pregabalin-administered patients
in Shiga University of Medical Science Hospital from
September 2010 to September 2012 except for exclusion
criteria (described below), and the subject number was
195. In these periods, pregabalin was prescribed from
the several clinical departments not only for the treat-
ment of cancer pain but also for that of neuropathic
pain, painful diabetic neuropathy, post-herpetic neuralgia,
fibromyalgia, post-operative neuropathy and chemotherapy-
induced peripheral neuropathy. The departments were as
followed: orthopedic surgery, hematology, dermatology,
respiratory medicine, thoracic surgery, urology, neurology,
otorhinolaryngology-head and neck surgery, endocrin-
ology and metabolism, neurosurgery, gastrointestinal sur-
gery, female pelvic surgery and reproductive medicine,
maternal and fetal medicine, pain management clinic,
nephrology and diabetes, cardiovascular surgery, general
surgery, physical medicine and rehabilitation, gastroenter-
ology, cardiology, emergency and I.C.U. and psychiatry.
The occurrences of somnolence or dizziness during the
administration of pregabalin were collected from medical
charts, which were recorded by medical staffs based on in-
terviews with the patients in daily clinical practice. Al-
though, due to the data collection method, the severity of
the adverse effects could not be evaluated, they might be
regarded as grade ≥1 of the Common Terminology Cri-
teria for Adverse Events version 4.0 because the data were
based on patients’ words. The patients who used pregaba-
lin on an as-needed basis, who were under 18 years old,
who were not prescribed pregabalin for the first time
and who did not have complete data for analysis were
excluded.
Collection of patient data
The data collected included basic demographic informa-
tion such as age, gender, serum creatinine level, duration
of pregabalin therapy, initial and maintenance doses of
pregabalin, administration protocol for pregabalin that
followed the defined one in the package insert, and con-
comitant drugs, which included NSAID, hypoglycemic
drugs, anti-hypertensive drugs, opioids and central ner-
vous system (CNS)-depressants excluding opioids, which
might contribute to the increase in the incidence of
somnolence and dizziness as adverse effects of pregaba-
lin. Duration of the pregabalin therapy of the patient
who prescribed pregabalin over the data collection
period was regarded as terminated in the last day of the
data collection period. The CLCr in patients were calcu-
lated using the Cockcroft-Gault equation.
Statistical analysis
Multivariate logistic regression analysis was performed
to determine predictors of adverse effects, the following
independent variables being included; CLCr, duration of
pregabalin therapy, initial dose, maintenance dose, and
defined/undefined doses of pregabalin, and concomitant
drugs. The CLCr values were significantly correlated
with age, and thus age was not used as an independent
variable to avoid multicollinearity. Statistical analysis
was performed using StatView 5.0 software (SAS Insti-
tute Inc.), a p-value of 0.05 or less being considered sta-
tistically significant.
Results
The basic characteristics of the 195 patients analyzed in
this study are summarized in Table 1. A total 334 pa-
tients were recruited, and after exclusion of 139 patients
based on the criteria described under Methods, complete
data were obtained for 195 patients (Fig. 1; 114 males and
81 females), whose median age, initial and maintenance
doses were 67.0 years old, 75 mg/day and 150 mg/day, re-
spectively. When the patients were classified as to their
renal function, 127 patients (65.1 %) with CLCr values of
more than 60 mL/min exhibited normal renal function, 55
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(28.2 %) with more than 30 to less than or equal 60 mL/
min mild renal dysfunction, and 13 (6.7 %) with less than
or equal 30 mL/min severe renal dysfunction. As for ad-
verse effects, there was no apparent difference in the inci-
dence of somnolence and dizziness among normal renal
function, and mild and severe renal dysfunction. The me-
dian initial doses of pregabalin in patients with normal
renal function, and mild and severe renal dysfunction be-
ing 150, 75 and 50 mg/day, respectively (Table 2). These
median doses are the same with the defined initial doses
for each patient based on the renal function.
Distribution of the number of patients whose duration
of pregabalin therapy for 2 week or less, more than
2 weeks to 1 month or less, more than 1 to 2 months or
less and more than 2 months were 21 (10.8 %), 30
(15.4 %), 36 (18.5 %) and 108 (55.4 %), respectively
(Table 3). There was no apparent difference in ratios of
the patients who developed adverse effects among each
period. However, first onset date of the adverse effects
from the start of pregabalin medication was the most
frequent within 2 weeks (Table 4).
As for the initial doses of pregabalin (Table 3), 166 pa-
tients (85.1 %) were prescribed it in the defined dose
range, while 29 (14.9 %) received more than the defined
doses, i.e., about 2-fold greater. The incidence of adverse
effect tended to be higher in patients who were pre-
scribed over the defined dose than in patients whose
doses were within the defined one.
As shown in Table 3, 115 patients received concomi-
tant drugs with pregabalin, hypoglycemic drugs, anti-
hypertensive drugs, NSAIDs, opioids and CNS-depressants
being prescribed to 28 (14.4 %), 55 (28.2 %), 64 (32.8 %),
54 (27.7 %) and 31 (15.9 %) patients, respectively, and the
numbers of patients with somnolence and dizziness being
6 (21.4 %), 15 (27.2 %), 15 (23.4 %), 25 (46.3 %) and 9
(29.0 %), respectively.
In Table 5, the odds ratios derived from multivariate
logistic regression model are summarized. Among ten
factors evaluated, concomitant use of opioids with preg-
abalin exhibited the statistically significant higher rate of
induction of somnolence and dizziness compared to
without them (odds ratio (OR) = 2.700, 95 % confidence
interval (CI) = 1.282–5.689, p = 0.009). Thus, among these
drugs, the concomitant administration of opioids with
pregabalin might have the high potential to induce som-
nolence and dizziness in patients. Incidence of somno-
lence and dizziness in patients who were prescribed
pregabalin without opioids were 19.9 and 14.9 %, and who
used pregabalin and opioids concomitantly were 35.2 and
24.1 %, respectively (Table 6). Four kinds of opioids were
used with pregabalin in 54 patients. Among them, oxy-
codone showed the highest incidence of adverse effects
(47.8 %). Other two opioids also induced the adverse ef-
fects in more than 25 % patients, but their sample size is
too small to analyze.
Discussion
A high incidence of somnolence and dizziness was de-
tected in the patients who had co-administration of
pregabalin and opioids. There was a tendency that ad-
verse effects were frequently developed in the early days
of pregabalin medication.
In the previous studies, the elderly patients tended to
have high serum concentrations of pregabalin [15] and a
high incidence of adverse effects of pregabalin [11],
which were reasonable considering their decreased renal
function. However, in the present study, there was no
difference in the incidence of adverse effects among each
renal function (Table 2). Although there seems to be a
discrepancy between the previous study and ours, it is
considered to be explained by the fine tuning of the
doses based on the renal function of the hospitalized pa-
tients as described below. The average of age and ratios
of the patients’ renal function in the interim report of
the drug use investigation of pregabalin are almost the
same with the population of this study [11]. The major
difference between two studies is patient population,
that is to say, population of our study is inpatients, in
Table 1 Characteristics of study population
Demographic factors N Median (range)
Male 114 (59.5 %)
Female 81 (41.5 %)
Age 67.0 (20–90)
Dose of pregabalin Median (range)
Initial dose, mg/day 75 (25–450)
Maintenance dose, mg/day 150 (25–450)
Adverse effects N
Patients who developed one
or both of side effects
63 (32.3 %)
Patients who developed somnolence 47 (24.1 %)
Patients who developed dizziness 34 (17.4 %)
Fig. 1 Schematic illustration of the exclusion criteria in this study
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contrast to outpatients in the previous report. Hospital-
ized patients were received their physical management
more strictly compared to the case of clinical trials. Dur-
ing hospitalization, patients were assessed their physical
condition such as renal function and efficacy/adverse ef-
fects of pregabalin in detail every day. The same as the
case of our study, the retrospective study on pregabalin
in hospital inpatients demonstrated that the renal func-
tion of the patients was not a significant risk factor for
induction of somnolence and dizziness [13, 14].
Kanbayashi et al. found that prolonged duration of
pregabalin therapy significantly increased the incidence
of somnolence [14]. On the other hand, in the present
study, duration of the pregabalin therapy was not de-
tected as the significant factor, and onsets of the adverse
effects were frequently detected in the early days of
pregabalin medication. Although these results are op-
posite to Kanbayashi’s one, it is reasonable that the ad-
verse effects developed frequently in the initiation phase
of pregabalin therapy, because this phase is in the dur-
ation of which titrate an appropriate dosage of pregaba-
lin for each patient. Additionally, maintenance dose of
the pregabalin was not identified as the significant factor
for incidence of adverse effects, either as with the report
of Kanbayashi’s one. From these results, it is conceivable
that the dosage of pregabalin was titrated with the
monitoring of the condition of adverse effects, according
to the defined usage of the pregabalin, which suggested
that start medication from low doses and escalate the
dose with the monitoring of the adverse effect develop-
ment. The present study reported the frequent develop-
ment of adverse effects of pregabalin in the initial phase
of the therapy for the first time. This finding supports
the defined usage of the pregabalin which suggested that
the dose should be escalated from low dosage. Together,
fine tuning of pregabalin dosing schedules for each pa-
tient based on their physical conditions is critical for its
safe and effective use.
Very recently, Watanabe et al. reported that concomi-
tant use of opioid was the risk factor of the somnolence
and dizziness in hospitalized patients [13]. This corre-
lates significantly with current result, although the num-
ber of assessed patients were not so large (n = 65), as
compared to the present study (n = 195). These findings
indicate that concomitant use of pregabalin and opioids
is a common risk factor for somnolence and dizziness,
and this finding is clinically important information. This
finding will be robust by the large-scale investigation
and meta-analysis.
Opioids have the same adverse effects, somnolence
and dizziness, as pregabalin, and thus we can not define
the underlying mechanism. In meta-analysis, median
Table 2 Renal function and prescribed doses







with over defined initial dose
>60 127 150 (25–450) 150 41 (32.3 %) 1 (2.4 %)
>30–≤60 55 75 (25–150) 75 17 (30.9 %) 8 (47.1 %)
≤30 13 50 (25–150) 25 or 50 5 (38.5 %) 2 (40.0 %)
Table 3 Characteristics of patients who developed dizziness or somnolence
Duration of pregabalin therapy N Developed somnolence or dizziness
≤2 weeks 21 (10.8 %) 8 (38.1 %)
>2 weeks–≤1 month 30 (15.4 %) 7 (23.3 %)
>1 month–≤2 months 36 (18.5 %) 11 (30.6 %)
>2 months 108 (55.4 %) 37 (34.3 %)
Median (day, range) 78 (1–740)
Dosage N Developed somnolence or dizziness
Within the defined initial dosage range 166 (85.1 %) 52 (31.3 %)
Over the defined initial dosage range 29 (14.9 %) 11 (37.9 %)
Concomitant drugs with pregabalin N Developed somnolence or dizziness
Oral hypoglycemic drugs 28 (14.4 %) 6 (21.4 %)
Antihypertensive drugs 55 (28.2 %) 15 (27.2 %)
NSAID 64 (32.8 %) 15 (23.4 %)
Opioid pain relievers 54 (27.7 %) 25 (46.3 %)
CNS- depressants 31 (15.9 %) 9 (29.0 %)
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occurrence rates of somnolence and dizziness in opioid-
treated patients were 21 % (range: 10–39 %) and 22 %
(range: 10–37 %), in pregabalin-treated patients were
13.7 % (range: 5.7–25.7 %) and 24.1 % (range: 8.7–
35.5 %), respectively [16, 17]. These data suggest that in-
cidences of somnolence and dizziness of both drugs are
the same level. In the present study, incidences of som-
nolence and dizziness of patients who used pregabalin
without opioids were 19.9 and 14.9 %, respectively. Since
we have not collected the data of patients who use opi-
oids without pregabalin, we can not evaluate the inci-
dence of somnolence and dizziness of them in those
patients. Both incidences of somnolence and dizziness of
patients who used pregabalin without opioids were in
the ranges of the result of meta-analysis. However, in the
present study, incidences of the adverse effects in pa-
tients who used pregabalin and opioids concomitantly
(somnolence: 35.2 %, dizziness: 24.1 %) were higher than
those of patients who used pregabalin without opioids.
This result suggested that increased incidence of adverse
effects might be caused by additive effect of opioids.
The target of pregabalin is the α2-δ1 auxiliary subunits
of voltage-dependent calcium channels, while that of
opioids is μ-opioid receptors, both of which activate the
descending noradrenergic system [18, 19]. A target of
gabapentin is reported to be the α2-δ1 subunits as
pregabalin [20, 21]. It appears that co-administration of
gabapentin and opioids leads to great anti-neuropathic
pain efficacy without an apparent increase of adverse ef-
fects [3, 4, 22]. This preferable interaction between gaba-
pentin and opioids is considered to be due to activation of
the descending noradrenergic system [23], but whether
their interaction is additive or synergetic remains un-
known, and there has been a report that concomitant ad-
ministration of morphine with gabapentin results in their
pharmacokinetic interaction, leading to an increased
serum concentration of gabapentin [24]. Since pregabalin
appears not to be metabolized and to have no effect on
functional expression of cytochrome P450 isozymes [25],
it is considered that there is no or only a negligible possi-
bility of a pharmacokinetic interaction between pregabalin
and opioids. On the other hand, it has been reported that
pregabalin exhibits 6-fold greater affinity for presynaptic
calcium channels than gabapentin [8, 9], and thus co-
administration of pregabalin and opioids might induce
their adverse effects to greater levels than in the case of
gabapentin. However, as described above, the severity of
the adverse effects have not evaluated and this study was a
retrospective one, and thus, precise rates of the incidence
of adverse effects were unclear. To clarify the mechanism
underlying this interaction, detail investigations are
needed.
Dou et al. (2014) investigated the efficacy and safety of
pregabalin in patients undergoing morphine therapy by
double-blind, randomized, placebo-controlled crossover
study [26]. They showed that combination use of the
pregabalin and morphine increased the incidence of
somnolence and dizziness, as like in the present study.
On the other hand, they also showed that concomitant
use of pregabalin contributes to reduce the dose of mor-
phine with the same pain-relief efficacy, compared to
that in morphine-monotherapy. These results suggest
that although combination use of the two drugs in-
creases the incidence of the adverse effects, their con-
comitant use could lead to avoid the dose-limiting
adverse effects such as nausea, constipation and vomit-
ing caused by morphine. Thus, concomitant use of
Table 4 Distribution of the first onset date of adverse effects
from the start of pregabalin medication
First onset date of
adverse effects
N (% of adverse effect developed patients)
≤2 weeks 46 (73.0 %)
>2 weeks–≤1 month 9 (14.3 %)
>1 month–≤2 months 1 (1.6 %)
>2 months 7 (11.1 %)
Table 5 Predictive value for each factor
Factor ORa 95 % CIb P value
CLCr 0.990 0.979–1.001 0.080
Duration of pregabalin therapy 0.999 0.998–1.001 0.521
Initial dose 1.000 0.992–1.008 0.945
Maintenance dose 1.003 0.998–1.009 0.187
Over the defined initial dose range 0.739 0.246–2.220 0.590
Hypoglycemic drug 0.607 0.221–1.670 0.333
Antihypertensive drug 0.707 0.340–1.471 0.354
NSAID 0.758 0.370–1.554 0.450
Opioid analgesic 2.700 1.282–5.689 0.009
CNS- depressant 0.622 0.248–1.562 0.312
aOR odds ratio
bCI confidence interval
Table 6 Prescribed opioids and the incidence of somnolence
and dizziness






Non-prescribed patients 141 28 (19.9 %) 21 (14.9 %)
Prescribed patients 54 19 (35.2 %) 13 (24.1 %)
Concomitant opioids N Developed somnolence or
dizziness
Fentanyl 26 7 (26.9 %)
Oxycodone 23 11 (47.8 %)
Tramadol 18 7 (38.9 %)
Morphine 4 0 (0 %)
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pregabalin and opioids should be performed with the
careful consideration of the risks and benefits.
All these independent investigations clearly demon-
strated that concomitant administration of opioids with
pregabalin has the potential to increase the incidence of
adverse effects, and that fine tuning of pregabalin dosing
schedules for each patient based on their physical condi-
tions is critical for its safe and effective use. Further ana-
lysis based on larger-scale database may provide more
exact information for risk factors.
In cancer chemotherapy including peripheral neuropathy-
inducible agents such as oxaliplatin [27], pregabalin is fre-
quently prescribed to the patients in addition to opioids
for prevention of somatic/visceral pain [28, 29]. Consider-
ing increase of numbers of the outpatients receiving
cancer chemotherapy in hospital, there is a possibility
that pregabalin is unexpectedly prescribed to opioid-
administered patients in clinics. In such outpatients,
there is an increasing possibility of development of som-
nolence and dizziness as the adverse effects of pregabalin/
opioid, resulting in falling and tumbling of them, because
pharmaceutical care is less than the case of inpatients. To
avoid such unexpected situation, information sharing
among medical staffs is crucial, and one of the effective
ways for its prevention is considered to use of medication
notebook [30, 31].
Conclusion
In conclusion, the present study revealed that concomi-
tant administration of opioids with pregabalin increased
the incidence of somnolence and dizziness in the patients,
and strict dosage schedule management based on the
renal function of individual patients is critical for safe and
effective neuropathic pain treatment using pregabalin.
Our findings are supported by recent other independent
studies, suggesting that severe potential risks may be in-
cluded for the co-administration of opioids with pregaba-
lin. For safer pharmacotherapy of pregabalin, concomitant
administration of opioids, in addition to age and renal
function, should be paid attention as risk factors.
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